#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Magnetoencephalographic and functional MRI connectomics in schizophrenia via intra- and inter-network connectivity Examination of intrinsic functional connectivity using functional MRI (fMRI) has provided important findings regarding dysconnectivity in schizophrenia.
1-1	0-23	Magnetoencephalographic	_
1-2	24-27	and	_
1-3	28-38	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
1-4	39-42	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
1-5	43-55	connectomics	_
1-6	56-58	in	_
1-7	59-72	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-8	73-76	via	_
1-9	77-83	intra-	_
1-10	84-87	and	_
1-11	88-101	inter-network	_
1-12	102-114	connectivity	_
1-13	115-126	Examination	_
1-14	127-129	of	_
1-15	130-139	intrinsic	_
1-16	140-150	functional	_
1-17	151-163	connectivity	_
1-18	164-169	using	_
1-19	170-180	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-20	181-184	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-21	185-186	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-22	187-191	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-23	192-193	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-24	194-197	has	_
1-25	198-206	provided	_
1-26	207-216	important	_
1-27	217-225	findings	_
1-28	226-235	regarding	_
1-29	236-251	dysconnectivity	_
1-30	252-254	in	_
1-31	255-268	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	269-270	.	_

Text=Extending these results using a complementary neuroimaging modality, magnetoencephalography (MEG), we present the first direct comparison of functional connectivity between schizophrenia patients and controls, using these two modalities combined.
2-1	271-280	Extending	_
2-2	281-286	these	_
2-3	287-294	results	_
2-4	295-300	using	_
2-5	301-302	a	_
2-6	303-316	complementary	_
2-7	317-329	neuroimaging	_
2-8	330-338	modality	_
2-9	339-340	,	_
2-10	341-363	magnetoencephalography	_
2-11	364-365	(	_
2-12	366-369	MEG	_
2-13	370-371	)	_
2-14	372-373	,	_
2-15	374-376	we	_
2-16	377-384	present	_
2-17	385-388	the	_
2-18	389-394	first	_
2-19	395-401	direct	_
2-20	402-412	comparison	_
2-21	413-415	of	_
2-22	416-426	functional	_
2-23	427-439	connectivity	_
2-24	440-447	between	_
2-25	448-461	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-26	462-470	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-27	471-474	and	_
2-28	475-483	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-29	484-485	,	_
2-30	486-491	using	_
2-31	492-497	these	_
2-32	498-501	two	_
2-33	502-512	modalities	_
2-34	513-521	combined	_
2-35	522-523	.	_

Text=We developed a novel MEG approach for estimation of networks using MEG that incorporates spatial independent component analysis (ICA) and pairwise correlations between independent component timecourses, to estimate intra- and intern-network connectivity.
3-1	524-526	We	_
3-2	527-536	developed	_
3-3	537-538	a	_
3-4	539-544	novel	_
3-5	545-548	MEG	_
3-6	549-557	approach	_
3-7	558-561	for	_
3-8	562-572	estimation	_
3-9	573-575	of	_
3-10	576-584	networks	_
3-11	585-590	using	_
3-12	591-594	MEG	_
3-13	595-599	that	_
3-14	600-612	incorporates	_
3-15	613-620	spatial	_
3-16	621-632	independent	_
3-17	633-642	component	_
3-18	643-651	analysis	_
3-19	652-653	(	_
3-20	654-657	ICA	_
3-21	658-659	)	_
3-22	660-663	and	_
3-23	664-672	pairwise	_
3-24	673-685	correlations	_
3-25	686-693	between	_
3-26	694-705	independent	_
3-27	706-715	component	_
3-28	716-727	timecourses	_
3-29	728-729	,	_
3-30	730-732	to	_
3-31	733-741	estimate	_
3-32	742-748	intra-	_
3-33	749-752	and	_
3-34	753-767	intern-network	_
3-35	768-780	connectivity	_
3-36	781-782	.	_

Text=This analysis enables group-level inference and testing of between-group differences.
4-1	783-787	This	_
4-2	788-796	analysis	_
4-3	797-804	enables	_
4-4	805-816	group-level	_
4-5	817-826	inference	_
4-6	827-830	and	_
4-7	831-838	testing	_
4-8	839-841	of	_
4-9	842-855	between-group	_
4-10	856-867	differences	_
4-11	868-869	.	_

Text=Resting state MEG and fMRI data were acquired from a large sample of healthy controls (n=45) and schizophrenia patients (n=46).
5-1	870-877	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-2	878-883	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-3	884-887	MEG	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-4	888-891	and	_
5-5	892-896	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	897-901	data	_
5-7	902-906	were	_
5-8	907-915	acquired	_
5-9	916-920	from	_
5-10	921-922	a	_
5-11	923-928	large	_
5-12	929-935	sample	_
5-13	936-938	of	_
5-14	939-946	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-15	947-955	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-16	956-957	(	_
5-17	958-962	n=45	_
5-18	963-964	)	_
5-19	965-968	and	_
5-20	969-982	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-21	983-991	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-22	992-993	(	_
5-23	994-998	n=46	_
5-24	999-1000	)	_
5-25	1001-1002	.	_

Text=Group spatial ICA was performed on fMRI and MEG data to extract intrinsic fMRI and MEG networks and to compensate for signal leakage in MEG.
6-1	1003-1008	Group	_
6-2	1009-1016	spatial	_
6-3	1017-1020	ICA	_
6-4	1021-1024	was	_
6-5	1025-1034	performed	_
6-6	1035-1037	on	_
6-7	1038-1042	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-8	1043-1046	and	_
6-9	1047-1050	MEG	_
6-10	1051-1055	data	_
6-11	1056-1058	to	_
6-12	1059-1066	extract	_
6-13	1067-1076	intrinsic	_
6-14	1077-1081	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-15	1082-1085	and	_
6-16	1086-1089	MEG	_
6-17	1090-1098	networks	_
6-18	1099-1102	and	_
6-19	1103-1105	to	_
6-20	1106-1116	compensate	_
6-21	1117-1120	for	_
6-22	1121-1127	signal	_
6-23	1128-1135	leakage	_
6-24	1136-1138	in	_
6-25	1139-1142	MEG	_
6-26	1143-1144	.	_

Text=Similar, but not identical spatial independent components were detected for MEG and fMRI.
7-1	1145-1152	Similar	_
7-2	1153-1154	,	_
7-3	1155-1158	but	_
7-4	1159-1162	not	_
7-5	1163-1172	identical	_
7-6	1173-1180	spatial	_
7-7	1181-1192	independent	_
7-8	1193-1203	components	_
7-9	1204-1208	were	_
7-10	1209-1217	detected	_
7-11	1218-1221	for	_
7-12	1222-1225	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
7-13	1226-1229	and	_
7-14	1230-1234	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-15	1235-1236	.	_

Text=Analysis of functional network connectivity (FNC; i.e., pairwise correlations in network (ICA component) timecourses) revealed a differential between-modalities pattern, with greater connectivity among occipital networks in fMRI and among frontal networks in MEG.
8-1	1237-1245	Analysis	_
8-2	1246-1248	of	_
8-3	1249-1259	functional	_
8-4	1260-1267	network	_
8-5	1268-1280	connectivity	_
8-6	1281-1282	(	_
8-7	1283-1286	FNC	_
8-8	1287-1288	;	_
8-9	1289-1293	i.e.	_
8-10	1294-1295	,	_
8-11	1296-1304	pairwise	_
8-12	1305-1317	correlations	_
8-13	1318-1320	in	_
8-14	1321-1328	network	_
8-15	1329-1330	(	_
8-16	1331-1334	ICA	_
8-17	1335-1344	component	_
8-18	1345-1346	)	_
8-19	1347-1358	timecourses	_
8-20	1359-1360	)	_
8-21	1361-1369	revealed	_
8-22	1370-1371	a	_
8-23	1372-1384	differential	_
8-24	1385-1403	between-modalities	_
8-25	1404-1411	pattern	_
8-26	1412-1413	,	_
8-27	1414-1418	with	_
8-28	1419-1426	greater	_
8-29	1427-1439	connectivity	_
8-30	1440-1445	among	_
8-31	1446-1455	occipital	_
8-32	1456-1464	networks	_
8-33	1465-1467	in	_
8-34	1468-1472	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-35	1473-1476	and	_
8-36	1477-1482	among	_
8-37	1483-1490	frontal	_
8-38	1491-1499	networks	_
8-39	1500-1502	in	_
8-40	1503-1506	MEG	_
8-41	1507-1508	.	_

Text=Most importantly, significant differences between controls and patients were observed in both modalities.
9-1	1509-1513	Most	_
9-2	1514-1525	importantly	_
9-3	1526-1527	,	_
9-4	1528-1539	significant	_
9-5	1540-1551	differences	_
9-6	1552-1559	between	_
9-7	1560-1568	controls	_
9-8	1569-1572	and	_
9-9	1573-1581	patients	_
9-10	1582-1586	were	_
9-11	1587-1595	observed	_
9-12	1596-1598	in	_
9-13	1599-1603	both	_
9-14	1604-1614	modalities	_
9-15	1615-1616	.	_

Text=MEG FNC results in particular indicated dysfunctional hyperconnectivity within frontal and temporal networks in patients, while in fMRI FNC was always greater for controls than for patients.
10-1	1617-1620	MEG	_
10-2	1621-1624	FNC	_
10-3	1625-1632	results	_
10-4	1633-1635	in	_
10-5	1636-1646	particular	_
10-6	1647-1656	indicated	_
10-7	1657-1670	dysfunctional	_
10-8	1671-1688	hyperconnectivity	_
10-9	1689-1695	within	_
10-10	1696-1703	frontal	_
10-11	1704-1707	and	_
10-12	1708-1716	temporal	_
10-13	1717-1725	networks	_
10-14	1726-1728	in	_
10-15	1729-1737	patients	_
10-16	1738-1739	,	_
10-17	1740-1745	while	_
10-18	1746-1748	in	_
10-19	1749-1753	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
10-20	1754-1757	FNC	_
10-21	1758-1761	was	_
10-22	1762-1768	always	_
10-23	1769-1776	greater	_
10-24	1777-1780	for	_
10-25	1781-1789	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-26	1790-1794	than	_
10-27	1795-1798	for	_
10-28	1799-1807	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-29	1808-1809	.	_

Text=This is the first study to apply group spatial ICA as an approach to leakage correction, and as such our results may be biased by spatial leakage effects.
11-1	1810-1814	This	_
11-2	1815-1817	is	_
11-3	1818-1821	the	_
11-4	1822-1827	first	_
11-5	1828-1833	study	_
11-6	1834-1836	to	_
11-7	1837-1842	apply	_
11-8	1843-1848	group	_
11-9	1849-1856	spatial	_
11-10	1857-1860	ICA	_
11-11	1861-1863	as	_
11-12	1864-1866	an	_
11-13	1867-1875	approach	_
11-14	1876-1878	to	_
11-15	1879-1886	leakage	_
11-16	1887-1897	correction	_
11-17	1898-1899	,	_
11-18	1900-1903	and	_
11-19	1904-1906	as	_
11-20	1907-1911	such	_
11-21	1912-1915	our	_
11-22	1916-1923	results	_
11-23	1924-1927	may	_
11-24	1928-1930	be	_
11-25	1931-1937	biased	_
11-26	1938-1940	by	_
11-27	1941-1948	spatial	_
11-28	1949-1956	leakage	_
11-29	1957-1964	effects	_
11-30	1965-1966	.	_

Text=Results suggest that combining these two neuroimaging modalities reveals additional disease-relevant patterns of connectivity that were not detectable with fMRI or MEG alone.
12-1	1967-1974	Results	_
12-2	1975-1982	suggest	_
12-3	1983-1987	that	_
12-4	1988-1997	combining	_
12-5	1998-2003	these	_
12-6	2004-2007	two	_
12-7	2008-2020	neuroimaging	_
12-8	2021-2031	modalities	_
12-9	2032-2039	reveals	_
12-10	2040-2050	additional	_
12-11	2051-2067	disease-relevant	_
12-12	2068-2076	patterns	_
12-13	2077-2079	of	_
12-14	2080-2092	connectivity	_
12-15	2093-2097	that	_
12-16	2098-2102	were	_
12-17	2103-2106	not	_
12-18	2107-2117	detectable	_
12-19	2118-2122	with	_
12-20	2123-2127	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-21	2128-2130	or	_
12-22	2131-2134	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
12-23	2135-2140	alone	_
12-24	2141-2142	.	_

Text=2.
13-1	2143-2144	2	_
13-2	2145-2146	.	_

Text=Materials and Methods 2.1 Participants This investigation combined existing data from 91 participants, 46 schizophrenia patients and 45 healthy controls.
14-1	2147-2156	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	2157-2160	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	2161-2168	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	2169-2172	2.1	_
14-5	2173-2185	Participants	_
14-6	2186-2190	This	_
14-7	2191-2204	investigation	_
14-8	2205-2213	combined	_
14-9	2214-2222	existing	_
14-10	2223-2227	data	_
14-11	2228-2232	from	_
14-12	2233-2235	91	_
14-13	2236-2248	participants	_
14-14	2249-2250	,	_
14-15	2251-2253	46	_
14-16	2254-2267	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-17	2268-2276	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-18	2277-2280	and	_
14-19	2281-2283	45	_
14-20	2284-2291	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-21	2292-2300	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-22	2301-2302	.	_

Text=Informed consent was obtained from all participants according to institutional guidelines at the University of New Mexico Human Research Protections Office (HRPO).
15-1	2303-2311	Informed	_
15-2	2312-2319	consent	_
15-3	2320-2323	was	_
15-4	2324-2332	obtained	_
15-5	2333-2337	from	_
15-6	2338-2341	all	_
15-7	2342-2354	participants	_
15-8	2355-2364	according	_
15-9	2365-2367	to	_
15-10	2368-2381	institutional	_
15-11	2382-2392	guidelines	_
15-12	2393-2395	at	_
15-13	2396-2399	the	_
15-14	2400-2410	University	_
15-15	2411-2413	of	_
15-16	2414-2417	New	_
15-17	2418-2424	Mexico	_
15-18	2425-2430	Human	_
15-19	2431-2439	Research	_
15-20	2440-2451	Protections	_
15-21	2452-2458	Office	_
15-22	2459-2460	(	_
15-23	2461-2465	HRPO	_
15-24	2466-2467	)	_
15-25	2468-2469	.	_

Text=All participants were compensated for their participation.
16-1	2470-2473	All	_
16-2	2474-2486	participants	_
16-3	2487-2491	were	_
16-4	2492-2503	compensated	_
16-5	2504-2507	for	_
16-6	2508-2513	their	_
16-7	2514-2527	participation	_
16-8	2528-2529	.	_

Text=Patients with a diagnosis of schizophrenia or schizoaffective disorder were invited to participate.
17-1	2530-2538	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-2	2539-2543	with	_
17-3	2544-2545	a	_
17-4	2546-2555	diagnosis	_
17-5	2556-2558	of	_
17-6	2559-2572	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-7	2573-2575	or	_
17-8	2576-2591	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
17-9	2592-2600	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
17-10	2601-2605	were	_
17-11	2606-2613	invited	_
17-12	2614-2616	to	_
17-13	2617-2628	participate	_
17-14	2629-2630	.	_

Text=Each patient completed the Structured Clinical Interview for DSM-IV Axis I Disorders for diagnostic confirmation and evaluation of co-morbidities.
18-1	2631-2635	Each	_
18-2	2636-2643	patient	_
18-3	2644-2653	completed	_
18-4	2654-2657	the	_
18-5	2658-2668	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-6	2669-2677	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-7	2678-2687	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-8	2688-2691	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-9	2692-2698	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-10	2699-2703	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-11	2704-2705	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-12	2706-2715	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-13	2716-2719	for	_
18-14	2720-2730	diagnostic	_
18-15	2731-2743	confirmation	_
18-16	2744-2747	and	_
18-17	2748-2758	evaluation	_
18-18	2759-2761	of	_
18-19	2762-2776	co-morbidities	_
18-20	2777-2778	.	_

Text=Patients with a history of neurological disorders including head trauma (loss of consciousness> 5 minutes), mental retardation, history of substance dependence, or active substance abuse (except for nicotine) within the past year were excluded, as were patients who were clinically unstable (e.g., in the previous month were discharged from the hospital or had any changes in their psychotropic medications).
19-1	2779-2787	Patients	_
19-2	2788-2792	with	_
19-3	2793-2794	a	_
19-4	2795-2802	history	_
19-5	2803-2805	of	_
19-6	2806-2818	neurological	_
19-7	2819-2828	disorders	_
19-8	2829-2838	including	_
19-9	2839-2843	head	_
19-10	2844-2850	trauma	_
19-11	2851-2852	(	_
19-12	2853-2857	loss	_
19-13	2858-2860	of	_
19-14	2861-2874	consciousness	_
19-15	2875-2876	>	_
19-16	2877-2878	5	_
19-17	2879-2886	minutes	_
19-18	2887-2888	)	_
19-19	2889-2890	,	_
19-20	2891-2897	mental	_
19-21	2898-2909	retardation	_
19-22	2910-2911	,	_
19-23	2912-2919	history	_
19-24	2920-2922	of	_
19-25	2923-2932	substance	_
19-26	2933-2943	dependence	_
19-27	2944-2945	,	_
19-28	2946-2948	or	_
19-29	2949-2955	active	_
19-30	2956-2965	substance	_
19-31	2966-2971	abuse	_
19-32	2972-2973	(	_
19-33	2974-2980	except	_
19-34	2981-2984	for	_
19-35	2985-2993	nicotine	_
19-36	2994-2995	)	_
19-37	2996-3002	within	_
19-38	3003-3006	the	_
19-39	3007-3011	past	_
19-40	3012-3016	year	_
19-41	3017-3021	were	_
19-42	3022-3030	excluded	_
19-43	3031-3032	,	_
19-44	3033-3035	as	_
19-45	3036-3040	were	_
19-46	3041-3049	patients	_
19-47	3050-3053	who	_
19-48	3054-3058	were	_
19-49	3059-3069	clinically	_
19-50	3070-3078	unstable	_
19-51	3079-3080	(	_
19-52	3081-3085	e.g.	_
19-53	3086-3087	,	_
19-54	3088-3090	in	_
19-55	3091-3094	the	_
19-56	3095-3103	previous	_
19-57	3104-3109	month	_
19-58	3110-3114	were	_
19-59	3115-3125	discharged	_
19-60	3126-3130	from	_
19-61	3131-3134	the	_
19-62	3135-3143	hospital	_
19-63	3144-3146	or	_
19-64	3147-3150	had	_
19-65	3151-3154	any	_
19-66	3155-3162	changes	_
19-67	3163-3165	in	_
19-68	3166-3171	their	_
19-69	3172-3184	psychotropic	_
19-70	3185-3196	medications	_
19-71	3197-3198	)	_
19-72	3199-3200	.	_

Text=Stability was also monitored throughout the study to confirm that patients had no clinically meaningful symptom changes.
20-1	3201-3210	Stability	_
20-2	3211-3214	was	_
20-3	3215-3219	also	_
20-4	3220-3229	monitored	_
20-5	3230-3240	throughout	_
20-6	3241-3244	the	_
20-7	3245-3250	study	_
20-8	3251-3253	to	_
20-9	3254-3261	confirm	_
20-10	3262-3266	that	_
20-11	3267-3275	patients	_
20-12	3276-3279	had	_
20-13	3280-3282	no	_
20-14	3283-3293	clinically	_
20-15	3294-3304	meaningful	_
20-16	3305-3312	symptom	_
20-17	3313-3320	changes	_
20-18	3321-3322	.	_

Text=All patients had a negative urine toxicology for drugs of abuse at the time of enrollment in the study.
21-1	3323-3326	All	_
21-2	3327-3335	patients	_
21-3	3336-3339	had	_
21-4	3340-3341	a	_
21-5	3342-3350	negative	_
21-6	3351-3356	urine	_
21-7	3357-3367	toxicology	_
21-8	3368-3371	for	_
21-9	3372-3377	drugs	_
21-10	3378-3380	of	_
21-11	3381-3386	abuse	_
21-12	3387-3389	at	_
21-13	3390-3393	the	_
21-14	3394-3398	time	_
21-15	3399-3401	of	_
21-16	3402-3412	enrollment	_
21-17	3413-3415	in	_
21-18	3416-3419	the	_
21-19	3420-3425	study	_
21-20	3426-3427	.	_

Text=Patients were treated with a variety of antipsychotic medications.
22-1	3428-3436	Patients	_
22-2	3437-3441	were	_
22-3	3442-3449	treated	_
22-4	3450-3454	with	_
22-5	3455-3456	a	_
22-6	3457-3464	variety	_
22-7	3465-3467	of	_
22-8	3468-3481	antipsychotic	_
22-9	3482-3493	medications	_
22-10	3494-3495	.	_

Text=The doses of antipsychotic medications were converted to olanzapine equivalents (see Table 1:).
23-1	3496-3499	The	_
23-2	3500-3505	doses	_
23-3	3506-3508	of	_
23-4	3509-3522	antipsychotic	_
23-5	3523-3534	medications	_
23-6	3535-3539	were	_
23-7	3540-3549	converted	_
23-8	3550-3552	to	_
23-9	3553-3563	olanzapine	_
23-10	3564-3575	equivalents	_
23-11	3576-3577	(	_
23-12	3578-3581	see	_
23-13	3582-3587	Table	_
23-14	3588-3589	1	_
23-15	3590-3591	:	_
23-16	3592-3593	)	_
23-17	3594-3595	.	_

Text=Healthy controls were recruited from the same geographic location and completed the SCID – Non-Patient Edition to rule out Axis I conditions.
24-1	3596-3603	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-2	3604-3612	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-3	3613-3617	were	_
24-4	3618-3627	recruited	_
24-5	3628-3632	from	_
24-6	3633-3636	the	_
24-7	3637-3641	same	_
24-8	3642-3652	geographic	_
24-9	3653-3661	location	_
24-10	3662-3665	and	_
24-11	3666-3675	completed	_
24-12	3676-3679	the	_
24-13	3680-3684	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-14	3685-3686	–	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-15	3687-3698	Non-Patient	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-16	3699-3706	Edition	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-17	3707-3709	to	_
24-18	3710-3714	rule	_
24-19	3715-3718	out	_
24-20	3719-3723	Axis	_
24-21	3724-3725	I	_
24-22	3726-3736	conditions	_
24-23	3737-3738	.	_

Text=Although patients and controls were not yoked, demographic characteristics including age, gender, and caregiver socio-economic status were monitored throughout recruitment to ensure that both groups were of similar composition.
25-1	3739-3747	Although	_
25-2	3748-3756	patients	_
25-3	3757-3760	and	_
25-4	3761-3769	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
25-5	3770-3774	were	_
25-6	3775-3778	not	_
25-7	3779-3784	yoked	_
25-8	3785-3786	,	_
25-9	3787-3798	demographic	_
25-10	3799-3814	characteristics	_
25-11	3815-3824	including	_
25-12	3825-3828	age	_
25-13	3829-3830	,	_
25-14	3831-3837	gender	_
25-15	3838-3839	,	_
25-16	3840-3843	and	_
25-17	3844-3853	caregiver	_
25-18	3854-3868	socio-economic	_
25-19	3869-3875	status	_
25-20	3876-3880	were	_
25-21	3881-3890	monitored	_
25-22	3891-3901	throughout	_
25-23	3902-3913	recruitment	_
25-24	3914-3916	to	_
25-25	3917-3923	ensure	_
25-26	3924-3928	that	_
25-27	3929-3933	both	_
25-28	3934-3940	groups	_
25-29	3941-3945	were	_
25-30	3946-3948	of	_
25-31	3949-3956	similar	_
25-32	3957-3968	composition	_
25-33	3969-3970	.	_

Text=There were no significant between-group differences on these measures (see Table 1), and results were largely unchanged when demographic characteristics were included as covariates.
26-1	3971-3976	There	_
26-2	3977-3981	were	_
26-3	3982-3984	no	_
26-4	3985-3996	significant	_
26-5	3997-4010	between-group	_
26-6	4011-4022	differences	_
26-7	4023-4025	on	_
26-8	4026-4031	these	_
26-9	4032-4040	measures	_
26-10	4041-4042	(	_
26-11	4043-4046	see	_
26-12	4047-4052	Table	_
26-13	4053-4054	1	_
26-14	4055-4056	)	_
26-15	4057-4058	,	_
26-16	4059-4062	and	_
26-17	4063-4070	results	_
26-18	4071-4075	were	_
26-19	4076-4083	largely	_
26-20	4084-4093	unchanged	_
26-21	4094-4098	when	_
26-22	4099-4110	demographic	_
26-23	4111-4126	characteristics	_
26-24	4127-4131	were	_
26-25	4132-4140	included	_
26-26	4141-4143	as	_
26-27	4144-4154	covariates	_
26-28	4155-4156	.	_

Text=All participant smokers were instructed not to use tobacco during the two hours prior to each scan to minimize acute effects.
27-1	4157-4160	All	_
27-2	4161-4172	participant	_
27-3	4173-4180	smokers	_
27-4	4181-4185	were	_
27-5	4186-4196	instructed	_
27-6	4197-4200	not	_
27-7	4201-4203	to	_
27-8	4204-4207	use	_
27-9	4208-4215	tobacco	_
27-10	4216-4222	during	_
27-11	4223-4226	the	_
27-12	4227-4230	two	_
27-13	4231-4236	hours	_
27-14	4237-4242	prior	_
27-15	4243-4245	to	_
27-16	4246-4250	each	_
27-17	4251-4255	scan	_
27-18	4256-4258	to	_
27-19	4259-4267	minimize	_
27-20	4268-4273	acute	_
27-21	4274-4281	effects	_
27-22	4282-4283	.	_

Text=This was confirmed via a breath carbon monoxide measure of less than 8 ppm.
28-1	4284-4288	This	_
28-2	4289-4292	was	_
28-3	4293-4302	confirmed	_
28-4	4303-4306	via	_
28-5	4307-4308	a	_
28-6	4309-4315	breath	_
28-7	4316-4322	carbon	_
28-8	4323-4331	monoxide	_
28-9	4332-4339	measure	_
28-10	4340-4342	of	_
28-11	4343-4347	less	_
28-12	4348-4352	than	_
28-13	4353-4354	8	_
28-14	4355-4358	ppm	_
28-15	4359-4360	.	_

Text=Each participant completed resting MEG and MRI scans.
29-1	4361-4365	Each	_
29-2	4366-4377	participant	_
29-3	4378-4387	completed	_
29-4	4388-4395	resting	_
29-5	4396-4399	MEG	_
29-6	4400-4403	and	_
29-7	4404-4407	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-8	4408-4413	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-9	4414-4415	.	_

Text=Scans were collected in counterbalanced order, with a median time between scans of approximately 22 days.
30-1	4416-4421	Scans	_
30-2	4422-4426	were	_
30-3	4427-4436	collected	_
30-4	4437-4439	in	_
30-5	4440-4455	counterbalanced	_
30-6	4456-4461	order	_
30-7	4462-4463	,	_
30-8	4464-4468	with	_
30-9	4469-4470	a	_
30-10	4471-4477	median	_
30-11	4478-4482	time	_
30-12	4483-4490	between	_
30-13	4491-4496	scans	_
30-14	4497-4499	of	_
30-15	4500-4513	approximately	_
30-16	4514-4516	22	_
30-17	4517-4521	days	_
30-18	4522-4523	.	_

Text=2.2 fMRI Data Acquisition All fMRI data were collected on a 3-Tesla Siemens Trio scanner with a 12-channel radio frequency coil.
31-1	4524-4527	2.2	_
31-2	4528-4532	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-3	4533-4537	Data	_
31-4	4538-4549	Acquisition	_
31-5	4550-4553	All	_
31-6	4554-4558	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-7	4559-4563	data	_
31-8	4564-4568	were	_
31-9	4569-4578	collected	_
31-10	4579-4581	on	_
31-11	4582-4583	a	_
31-12	4584-4591	3-Tesla	_
31-13	4592-4599	Siemens	_
31-14	4600-4604	Trio	_
31-15	4605-4612	scanner	_
31-16	4613-4617	with	_
31-17	4618-4619	a	_
31-18	4620-4630	12-channel	_
31-19	4631-4636	radio	_
31-20	4637-4646	frequency	_
31-21	4647-4651	coil	_
31-22	4652-4653	.	_

Text=High-resolution T1-weighted structural images were acquired with a five-echo MPRAGE sequence with TE = 1.64, 3.5, 5.36, 7.22, 9.08 ms, TR = 2.53 s, TI = 1.2 s, flip angle = 7°, number of excitations = 1, slice thickness = 1 mm, field of view = 256 mm, resolution = 256×256.
32-1	4654-4669	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
32-2	4670-4681	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-3	4682-4692	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-4	4693-4699	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-5	4700-4704	were	_
32-6	4705-4713	acquired	_
32-7	4714-4718	with	_
32-8	4719-4720	a	_
32-9	4721-4730	five-echo	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
32-10	4731-4737	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
32-11	4738-4746	sequence	_
32-12	4747-4751	with	_
32-13	4752-4754	TE	_
32-14	4755-4756	=	_
32-15	4757-4761	1.64	_
32-16	4762-4763	,	_
32-17	4764-4767	3.5	_
32-18	4768-4769	,	_
32-19	4770-4774	5.36	_
32-20	4775-4776	,	_
32-21	4777-4781	7.22	_
32-22	4782-4783	,	_
32-23	4784-4788	9.08	_
32-24	4789-4791	ms	_
32-25	4792-4793	,	_
32-26	4794-4796	TR	_
32-27	4797-4798	=	_
32-28	4799-4803	2.53	_
32-29	4804-4805	s	_
32-30	4806-4807	,	_
32-31	4808-4810	TI	_
32-32	4811-4812	=	_
32-33	4813-4816	1.2	_
32-34	4817-4818	s	_
32-35	4819-4820	,	_
32-36	4821-4825	flip	_
32-37	4826-4831	angle	_
32-38	4832-4833	=	_
32-39	4834-4836	7°	_
32-40	4837-4838	,	_
32-41	4839-4845	number	_
32-42	4846-4848	of	_
32-43	4849-4860	excitations	_
32-44	4861-4862	=	_
32-45	4863-4864	1	_
32-46	4865-4866	,	_
32-47	4867-4872	slice	_
32-48	4873-4882	thickness	_
32-49	4883-4884	=	_
32-50	4885-4886	1	_
32-51	4887-4889	mm	_
32-52	4890-4891	,	_
32-53	4892-4897	field	_
32-54	4898-4900	of	_
32-55	4901-4905	view	_
32-56	4906-4907	=	_
32-57	4908-4911	256	_
32-58	4912-4914	mm	_
32-59	4915-4916	,	_
32-60	4917-4927	resolution	_
32-61	4928-4929	=	_
32-62	4930-4937	256×256	_
32-63	4938-4939	.	_

Text=T2 * -weighted functional images were acquired using a gradient-echo EPI sequence with TE = 29 ms, TR = 2 s, flip angle = 75°, slice thickness = 3.5 mm, slice gap = 1.05 mm, field of view 240 mm, matrix size = 64x64, voxel size = 3.75 mm×3.75 mm×4.55 mm.
33-1	4940-4942	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-2	4943-4944	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-3	4945-4954	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-4	4955-4965	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-5	4966-4972	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-6	4973-4977	were	_
33-7	4978-4986	acquired	_
33-8	4987-4992	using	_
33-9	4993-4994	a	_
33-10	4995-5008	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-11	5009-5012	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-12	5013-5021	sequence	_
33-13	5022-5026	with	_
33-14	5027-5029	TE	_
33-15	5030-5031	=	_
33-16	5032-5034	29	_
33-17	5035-5037	ms	_
33-18	5038-5039	,	_
33-19	5040-5042	TR	_
33-20	5043-5044	=	_
33-21	5045-5046	2	_
33-22	5047-5048	s	_
33-23	5049-5050	,	_
33-24	5051-5055	flip	_
33-25	5056-5061	angle	_
33-26	5062-5063	=	_
33-27	5064-5067	75°	_
33-28	5068-5069	,	_
33-29	5070-5075	slice	_
33-30	5076-5085	thickness	_
33-31	5086-5087	=	_
33-32	5088-5091	3.5	_
33-33	5092-5094	mm	_
33-34	5095-5096	,	_
33-35	5097-5102	slice	_
33-36	5103-5106	gap	_
33-37	5107-5108	=	_
33-38	5109-5113	1.05	_
33-39	5114-5116	mm	_
33-40	5117-5118	,	_
33-41	5119-5124	field	_
33-42	5125-5127	of	_
33-43	5128-5132	view	_
33-44	5133-5136	240	_
33-45	5137-5139	mm	_
33-46	5140-5141	,	_
33-47	5142-5148	matrix	_
33-48	5149-5153	size	_
33-49	5154-5155	=	_
33-50	5156-5161	64x64	_
33-51	5162-5163	,	_
33-52	5164-5169	voxel	_
33-53	5170-5174	size	_
33-54	5175-5176	=	_
33-55	5177-5181	3.75	_
33-56	5182-5189	mm×3.75	_
33-57	5190-5197	mm×4.55	_
33-58	5198-5200	mm	_
33-59	5201-5202	.	_

Text=Resting-state scans consisted of 149 volumes per run.
34-1	5203-5216	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
34-2	5217-5222	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
34-3	5223-5232	consisted	_
34-4	5233-5235	of	_
34-5	5236-5239	149	_
34-6	5240-5247	volumes	_
34-7	5248-5251	per	_
34-8	5252-5255	run	_
34-9	5256-5257	.	_

Text=2.3 fMRI Data Preprocessing An automated preprocessing pipeline and neuroinformatics system developed at MRN was used to preprocess the fMRI data.
35-1	5258-5261	2.3	_
35-2	5262-5266	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-3	5267-5271	Data	_
35-4	5272-5285	Preprocessing	_
35-5	5286-5288	An	_
35-6	5289-5298	automated	_
35-7	5299-5312	preprocessing	_
35-8	5313-5321	pipeline	_
35-9	5322-5325	and	_
35-10	5326-5342	neuroinformatics	_
35-11	5343-5349	system	_
35-12	5350-5359	developed	_
35-13	5360-5362	at	_
35-14	5363-5366	MRN	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-15	5367-5370	was	_
35-16	5371-5375	used	_
35-17	5376-5378	to	_
35-18	5379-5389	preprocess	_
35-19	5390-5393	the	_
35-20	5394-5398	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-21	5399-5403	data	_
35-22	5404-5405	.	_

Text=The first four volumes were discarded to remove T1 equilibration effects.
36-1	5406-5409	The	_
36-2	5410-5415	first	_
36-3	5416-5420	four	_
36-4	5421-5428	volumes	_
36-5	5429-5433	were	_
36-6	5434-5443	discarded	_
36-7	5444-5446	to	_
36-8	5447-5453	remove	_
36-9	5454-5456	T1	_
36-10	5457-5470	equilibration	_
36-11	5471-5478	effects	_
36-12	5479-5480	.	_

Text=Images were realigned and slice-timing correction was applied using the middle slice as the reference frame in the functional data pipeline.
37-1	5481-5487	Images	_
37-2	5488-5492	were	_
37-3	5493-5502	realigned	_
37-4	5503-5506	and	_
37-5	5507-5519	slice-timing	_
37-6	5520-5530	correction	_
37-7	5531-5534	was	_
37-8	5535-5542	applied	_
37-9	5543-5548	using	_
37-10	5549-5552	the	_
37-11	5553-5559	middle	_
37-12	5560-5565	slice	_
37-13	5566-5568	as	_
37-14	5569-5572	the	_
37-15	5573-5582	reference	_
37-16	5583-5588	frame	_
37-17	5589-5591	in	_
37-18	5592-5595	the	_
37-19	5596-5606	functional	_
37-20	5607-5611	data	_
37-21	5612-5620	pipeline	_
37-22	5621-5622	.	_

Text=The data were then spatially normalized to the standard MNI space, resampled to 3×3× 3 mm voxels, and smoothed using a Gaussian kernel with a full-width at half-maximum (FWHM) of 10 mm.
38-1	5623-5626	The	_
38-2	5627-5631	data	_
38-3	5632-5636	were	_
38-4	5637-5641	then	_
38-5	5642-5651	spatially	_
38-6	5652-5662	normalized	_
38-7	5663-5665	to	_
38-8	5666-5669	the	_
38-9	5670-5678	standard	_
38-10	5679-5682	MNI	_
38-11	5683-5688	space	_
38-12	5689-5690	,	_
38-13	5691-5700	resampled	_
38-14	5701-5703	to	_
38-15	5704-5708	3×3×	_
38-16	5709-5710	3	_
38-17	5711-5713	mm	_
38-18	5714-5720	voxels	_
38-19	5721-5722	,	_
38-20	5723-5726	and	_
38-21	5727-5735	smoothed	_
38-22	5736-5741	using	_
38-23	5742-5743	a	_
38-24	5744-5752	Gaussian	_
38-25	5753-5759	kernel	_
38-26	5760-5764	with	_
38-27	5765-5766	a	_
38-28	5767-5777	full-width	_
38-29	5778-5780	at	_
38-30	5781-5793	half-maximum	_
38-31	5794-5795	(	_
38-32	5796-5800	FWHM	_
38-33	5801-5802	)	_
38-34	5803-5805	of	_
38-35	5806-5808	10	_
38-36	5809-5811	mm	_
38-37	5812-5813	.	_

Text=The preprocessed time series data were scaled to a mean of 100.
39-1	5814-5817	The	_
39-2	5818-5830	preprocessed	_
39-3	5831-5835	time	_
39-4	5836-5842	series	_
39-5	5843-5847	data	_
39-6	5848-5852	were	_
39-7	5853-5859	scaled	_
39-8	5860-5862	to	_
39-9	5863-5864	a	_
39-10	5865-5869	mean	_
39-11	5870-5872	of	_
39-12	5873-5876	100	_
39-13	5877-5878	.	_

Text=2.4 fMRI Group Spatial Independent Component Analysis (gsICA) Following Allen et al., we performed a subject-specific data reduction PCA retaining 100 principal components (PC).
40-1	5879-5882	2.4	_
40-2	5883-5887	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-3	5888-5893	Group	_
40-4	5894-5901	Spatial	_
40-5	5902-5913	Independent	_
40-6	5914-5923	Component	_
40-7	5924-5932	Analysis	_
40-8	5933-5934	(	_
40-9	5935-5940	gsICA	_
40-10	5941-5942	)	_
40-11	5943-5952	Following	_
40-12	5953-5958	Allen	_
40-13	5959-5961	et	_
40-14	5962-5965	al.	_
40-15	5966-5967	,	_
40-16	5968-5970	we	_
40-17	5971-5980	performed	_
40-18	5981-5982	a	_
40-19	5983-5999	subject-specific	_
40-20	6000-6004	data	_
40-21	6005-6014	reduction	_
40-22	6015-6018	PCA	_
40-23	6019-6028	retaining	_
40-24	6029-6032	100	_
40-25	6033-6042	principal	_
40-26	6043-6053	components	_
40-27	6054-6055	(	_
40-28	6056-6058	PC	_
40-29	6059-6060	)	_
40-30	6061-6062	.	_

Text=In order to use memory more efficiently, group data reduction was performed using an EM-based PCA algorithm and C = 75 PCs were retained.
41-1	6063-6065	In	_
41-2	6066-6071	order	_
41-3	6072-6074	to	_
41-4	6075-6078	use	_
41-5	6079-6085	memory	_
41-6	6086-6090	more	_
41-7	6091-6102	efficiently	_
41-8	6103-6104	,	_
41-9	6105-6110	group	_
41-10	6111-6115	data	_
41-11	6116-6125	reduction	_
41-12	6126-6129	was	_
41-13	6130-6139	performed	_
41-14	6140-6145	using	_
41-15	6146-6148	an	_
41-16	6149-6157	EM-based	_
41-17	6158-6161	PCA	_
41-18	6162-6171	algorithm	_
41-19	6172-6175	and	_
41-20	6176-6177	C	_
41-21	6178-6179	=	_
41-22	6180-6182	75	_
41-23	6183-6186	PCs	_
41-24	6187-6191	were	_
41-25	6192-6200	retained	_
41-26	6201-6202	.	_

Text=The infomax algorithm (cf.)
42-1	6203-6206	The	_
42-2	6207-6214	infomax	_
42-3	6215-6224	algorithm	_
42-4	6225-6226	(	_
42-5	6227-6229	cf	_
42-6	6230-6231	.	_
42-7	6232-6233	)	_

Text=was used for gICA.
43-1	6234-6237	was	_
43-2	6238-6242	used	_
43-3	6243-6246	for	_
43-4	6247-6251	gICA	_
43-5	6252-6253	.	_

Text=It was performed using the GIFT Toolbox (http: //mialab.mrn.org/software/gift/).
44-1	6254-6256	It	_
44-2	6257-6260	was	_
44-3	6261-6270	performed	_
44-4	6271-6276	using	_
44-5	6277-6280	the	_
44-6	6281-6285	GIFT	_
44-7	6286-6293	Toolbox	_
44-8	6294-6295	(	_
44-9	6296-6300	http	_
44-10	6301-6302	:	_
44-11	6303-6334	//mialab.mrn.org/software/gift/	_
44-12	6335-6336	)	_
44-13	6337-6338	.	_

Text=This high model order ICA (number of components, C = 75) affords a number of advantages, including the ability to use the resulting FNC matrix to infer how components would group in the case of a lower-dimension estimation, as well as refined components that correspond to known anatomical and functional segmentation.
45-1	6339-6343	This	_
45-2	6344-6348	high	_
45-3	6349-6354	model	_
45-4	6355-6360	order	_
45-5	6361-6364	ICA	_
45-6	6365-6366	(	_
45-7	6367-6373	number	_
45-8	6374-6376	of	_
45-9	6377-6387	components	_
45-10	6388-6389	,	_
45-11	6390-6391	C	_
45-12	6392-6393	=	_
45-13	6394-6396	75	_
45-14	6397-6398	)	_
45-15	6399-6406	affords	_
45-16	6407-6408	a	_
45-17	6409-6415	number	_
45-18	6416-6418	of	_
45-19	6419-6429	advantages	_
45-20	6430-6431	,	_
45-21	6432-6441	including	_
45-22	6442-6445	the	_
45-23	6446-6453	ability	_
45-24	6454-6456	to	_
45-25	6457-6460	use	_
45-26	6461-6464	the	_
45-27	6465-6474	resulting	_
45-28	6475-6478	FNC	_
45-29	6479-6485	matrix	_
45-30	6486-6488	to	_
45-31	6489-6494	infer	_
45-32	6495-6498	how	_
45-33	6499-6509	components	_
45-34	6510-6515	would	_
45-35	6516-6521	group	_
45-36	6522-6524	in	_
45-37	6525-6528	the	_
45-38	6529-6533	case	_
45-39	6534-6536	of	_
45-40	6537-6538	a	_
45-41	6539-6554	lower-dimension	_
45-42	6555-6565	estimation	_
45-43	6566-6567	,	_
45-44	6568-6570	as	_
45-45	6571-6575	well	_
45-46	6576-6578	as	_
45-47	6579-6586	refined	_
45-48	6587-6597	components	_
45-49	6598-6602	that	_
45-50	6603-6613	correspond	_
45-51	6614-6616	to	_
45-52	6617-6622	known	_
45-53	6623-6633	anatomical	_
45-54	6634-6637	and	_
45-55	6638-6648	functional	_
45-56	6649-6661	segmentation	_
45-57	6662-6663	.	_

Text=In order to estimate the reliability of the decomposition, the Infomax ICA algorithm was applied repeatedly via ICASSO and resulting components were clustered.
46-1	6664-6666	In	_
46-2	6667-6672	order	_
46-3	6673-6675	to	_
46-4	6676-6684	estimate	_
46-5	6685-6688	the	_
46-6	6689-6700	reliability	_
46-7	6701-6703	of	_
46-8	6704-6707	the	_
46-9	6708-6721	decomposition	_
46-10	6722-6723	,	_
46-11	6724-6727	the	_
46-12	6728-6735	Infomax	_
46-13	6736-6739	ICA	_
46-14	6740-6749	algorithm	_
46-15	6750-6753	was	_
46-16	6754-6761	applied	_
46-17	6762-6772	repeatedly	_
46-18	6773-6776	via	_
46-19	6777-6783	ICASSO	_
46-20	6784-6787	and	_
46-21	6788-6797	resulting	_
46-22	6798-6808	components	_
46-23	6809-6813	were	_
46-24	6814-6823	clustered	_
46-25	6824-6825	.	_

Text=Subject-specific maps and timecourses were estimated using a back-reconstruction approach based on PCA compression and projection.
47-1	6826-6842	Subject-specific	_
47-2	6843-6847	maps	_
47-3	6848-6851	and	_
47-4	6852-6863	timecourses	_
47-5	6864-6868	were	_
47-6	6869-6878	estimated	_
47-7	6879-6884	using	_
47-8	6885-6886	a	_
47-9	6887-6906	back-reconstruction	_
47-10	6907-6915	approach	_
47-11	6916-6921	based	_
47-12	6922-6924	on	_
47-13	6925-6928	PCA	_
47-14	6929-6940	compression	_
47-15	6941-6944	and	_
47-16	6945-6955	projection	_
47-17	6956-6957	.	_

Text=2.5 fMRI Feature Identification To identify non-artifactual components that contain features associated with resting state networks a combination of two methods was used.
48-1	6958-6961	2.5	_
48-2	6962-6966	fMRI	_
48-3	6967-6974	Feature	_
48-4	6975-6989	Identification	_
48-5	6990-6992	To	_
48-6	6993-7001	identify	_
48-7	7002-7017	non-artifactual	_
48-8	7018-7028	components	_
48-9	7029-7033	that	_
48-10	7034-7041	contain	_
48-11	7042-7050	features	_
48-12	7051-7061	associated	_
48-13	7062-7066	with	_
48-14	7067-7074	resting	_
48-15	7075-7080	state	_
48-16	7081-7089	networks	_
48-17	7090-7091	a	_
48-18	7092-7103	combination	_
48-19	7104-7106	of	_
48-20	7107-7110	two	_
48-21	7111-7118	methods	_
48-22	7119-7122	was	_
48-23	7123-7127	used	_
48-24	7128-7129	.	_

Text=In the first method we examined the power spectra with two criteria in mind: dynamic range and low frequency/high frequency ratio.
49-1	7130-7132	In	_
49-2	7133-7136	the	_
49-3	7137-7142	first	_
49-4	7143-7149	method	_
49-5	7150-7152	we	_
49-6	7153-7161	examined	_
49-7	7162-7165	the	_
49-8	7166-7171	power	_
49-9	7172-7179	spectra	_
49-10	7180-7184	with	_
49-11	7185-7188	two	_
49-12	7189-7197	criteria	_
49-13	7198-7200	in	_
49-14	7201-7205	mind	_
49-15	7206-7207	:	_
49-16	7208-7215	dynamic	_
49-17	7216-7221	range	_
49-18	7222-7225	and	_
49-19	7226-7229	low	_
49-20	7230-7244	frequency/high	_
49-21	7245-7254	frequency	_
49-22	7255-7260	ratio	_
49-23	7261-7262	.	_

Text=Dynamic range refers to the difference between the peak power and minimum power at frequencies to the right of the peak in the power spectra.
50-1	7263-7270	Dynamic	_
50-2	7271-7276	range	_
50-3	7277-7283	refers	_
50-4	7284-7286	to	_
50-5	7287-7290	the	_
50-6	7291-7301	difference	_
50-7	7302-7309	between	_
50-8	7310-7313	the	_
50-9	7314-7318	peak	_
50-10	7319-7324	power	_
50-11	7325-7328	and	_
50-12	7329-7336	minimum	_
50-13	7337-7342	power	_
50-14	7343-7345	at	_
50-15	7346-7357	frequencies	_
50-16	7358-7360	to	_
50-17	7361-7364	the	_
50-18	7365-7370	right	_
50-19	7371-7373	of	_
50-20	7374-7377	the	_
50-21	7378-7382	peak	_
50-22	7383-7385	in	_
50-23	7386-7389	the	_
50-24	7390-7395	power	_
50-25	7396-7403	spectra	_
50-26	7404-7405	.	_

Text=Low frequency to high frequency power ratio is the ratio of the integral of spectral power below 0.10 Hz to the integral of power between 0.15 and 0.25 Hz.
51-1	7406-7409	Low	_
51-2	7410-7419	frequency	_
51-3	7420-7422	to	_
51-4	7423-7427	high	_
51-5	7428-7437	frequency	_
51-6	7438-7443	power	_
51-7	7444-7449	ratio	_
51-8	7450-7452	is	_
51-9	7453-7456	the	_
51-10	7457-7462	ratio	_
51-11	7463-7465	of	_
51-12	7466-7469	the	_
51-13	7470-7478	integral	_
51-14	7479-7481	of	_
51-15	7482-7490	spectral	_
51-16	7491-7496	power	_
51-17	7497-7502	below	_
51-18	7503-7507	0.10	_
51-19	7508-7510	Hz	_
51-20	7511-7513	to	_
51-21	7514-7517	the	_
51-22	7518-7526	integral	_
51-23	7527-7529	of	_
51-24	7530-7535	power	_
51-25	7536-7543	between	_
51-26	7544-7548	0.15	_
51-27	7549-7552	and	_
51-28	7553-7557	0.25	_
51-29	7558-7560	Hz	_
51-30	7561-7562	.	_

Text=To verify the results, three expert reviewers evaluated the components for functional relevance.
52-1	7563-7565	To	_
52-2	7566-7572	verify	_
52-3	7573-7576	the	_
52-4	7577-7584	results	_
52-5	7585-7586	,	_
52-6	7587-7592	three	_
52-7	7593-7599	expert	_
52-8	7600-7609	reviewers	_
52-9	7610-7619	evaluated	_
52-10	7620-7623	the	_
52-11	7624-7634	components	_
52-12	7635-7638	for	_
52-13	7639-7649	functional	_
52-14	7650-7659	relevance	_
52-15	7660-7661	.	_

Text=In this evaluation, if a component exhibited 1) peak activation in gray matter, 2) low spatial overlap with known vascular, ventricular, motion, and susceptibility artifacts, and 3) TCs dominated by low frequency fluctuations, it was classified as a non-artifactual component.
53-1	7662-7664	In	_
53-2	7665-7669	this	_
53-3	7670-7680	evaluation	_
53-4	7681-7682	,	_
53-5	7683-7685	if	_
53-6	7686-7687	a	_
53-7	7688-7697	component	_
53-8	7698-7707	exhibited	_
53-9	7708-7709	1	_
53-10	7710-7711	)	_
53-11	7712-7716	peak	_
53-12	7717-7727	activation	_
53-13	7728-7730	in	_
53-14	7731-7735	gray	_
53-15	7736-7742	matter	_
53-16	7743-7744	,	_
53-17	7745-7746	2	_
53-18	7747-7748	)	_
53-19	7749-7752	low	_
53-20	7753-7760	spatial	_
53-21	7761-7768	overlap	_
53-22	7769-7773	with	_
53-23	7774-7779	known	_
53-24	7780-7788	vascular	_
53-25	7789-7790	,	_
53-26	7791-7802	ventricular	_
53-27	7803-7804	,	_
53-28	7805-7811	motion	_
53-29	7812-7813	,	_
53-30	7814-7817	and	_
53-31	7818-7832	susceptibility	_
53-32	7833-7842	artifacts	_
53-33	7843-7844	,	_
53-34	7845-7848	and	_
53-35	7849-7850	3	_
53-36	7851-7852	)	_
53-37	7853-7856	TCs	_
53-38	7857-7866	dominated	_
53-39	7867-7869	by	_
53-40	7870-7873	low	_
53-41	7874-7883	frequency	_
53-42	7884-7896	fluctuations	_
53-43	7897-7898	,	_
53-44	7899-7901	it	_
53-45	7902-7905	was	_
53-46	7906-7916	classified	_
53-47	7917-7919	as	_
53-48	7920-7921	a	_
53-49	7922-7937	non-artifactual	_
53-50	7938-7947	component	_
53-51	7948-7949	.	_

Text=Of the 75 components returned by the gICA, 39 were identified as BOLD-related component; see Fig.
54-1	7950-7952	Of	_
54-2	7953-7956	the	_
54-3	7957-7959	75	_
54-4	7960-7970	components	_
54-5	7971-7979	returned	_
54-6	7980-7982	by	_
54-7	7983-7986	the	_
54-8	7987-7991	gICA	_
54-9	7992-7993	,	_
54-10	7994-7996	39	_
54-11	7997-8001	were	_
54-12	8002-8012	identified	_
54-13	8013-8015	as	_
54-14	8016-8028	BOLD-related	_
54-15	8029-8038	component	_
54-16	8039-8040	;	_
54-17	8041-8044	see	_
54-18	8045-8048	Fig	_
54-19	8049-8050	.	_

Text=S1.
55-1	8051-8053	S1	_
55-2	8054-8055	.	_

Text=2.6 MEG data acquisition MEG data were collected in a magnetically and electrically shielded room (VAC Series Ak3B, Vacuumschmelze GmbH) using a whole-cortex 306-channel MEG array (Elekta Neuromag™) at the Mind Research Network.
56-1	8056-8059	2.6	_
56-2	8060-8063	MEG	_
56-3	8064-8068	data	_
56-4	8069-8080	acquisition	_
56-5	8081-8084	MEG	_
56-6	8085-8089	data	_
56-7	8090-8094	were	_
56-8	8095-8104	collected	_
56-9	8105-8107	in	_
56-10	8108-8109	a	_
56-11	8110-8122	magnetically	_
56-12	8123-8126	and	_
56-13	8127-8139	electrically	_
56-14	8140-8148	shielded	_
56-15	8149-8153	room	_
56-16	8154-8155	(	_
56-17	8156-8159	VAC	_
56-18	8160-8166	Series	_
56-19	8167-8171	Ak3B	_
56-20	8172-8173	,	_
56-21	8174-8188	Vacuumschmelze	_
56-22	8189-8193	GmbH	_
56-23	8194-8195	)	_
56-24	8196-8201	using	_
56-25	8202-8203	a	_
56-26	8204-8216	whole-cortex	_
56-27	8217-8228	306-channel	_
56-28	8229-8232	MEG	_
56-29	8233-8238	array	_
56-30	8239-8240	(	_
56-31	8241-8247	Elekta	_
56-32	8248-8257	Neuromag™	_
56-33	8258-8259	)	_
56-34	8260-8262	at	_
56-35	8263-8266	the	_
56-36	8267-8271	Mind	_
56-37	8272-8280	Research	_
56-38	8281-8288	Network	_
56-39	8289-8290	.	_

Text=Before positioning the participant in the MEG, four coils were affixed to the participant ’ s head: two on the forehead and one behind each ear.
57-1	8291-8297	Before	_
57-2	8298-8309	positioning	_
57-3	8310-8313	the	_
57-4	8314-8325	participant	_
57-5	8326-8328	in	_
57-6	8329-8332	the	_
57-7	8333-8336	MEG	_
57-8	8337-8338	,	_
57-9	8339-8343	four	_
57-10	8344-8349	coils	_
57-11	8350-8354	were	_
57-12	8355-8362	affixed	_
57-13	8363-8365	to	_
57-14	8366-8369	the	_
57-15	8370-8381	participant	_
57-16	8382-8383	’	_
57-17	8384-8385	s	_
57-18	8386-8390	head	_
57-19	8391-8392	:	_
57-20	8393-8396	two	_
57-21	8397-8399	on	_
57-22	8400-8403	the	_
57-23	8404-8412	forehead	_
57-24	8413-8416	and	_
57-25	8417-8420	one	_
57-26	8421-8427	behind	_
57-27	8428-8432	each	_
57-28	8433-8436	ear	_
57-29	8437-8438	.	_

Text=These coils allow determination of the position of the participant ’ s head relative to the position and orientation of the MEG sensors.
58-1	8439-8444	These	_
58-2	8445-8450	coils	_
58-3	8451-8456	allow	_
58-4	8457-8470	determination	_
58-5	8471-8473	of	_
58-6	8474-8477	the	_
58-7	8478-8486	position	_
58-8	8487-8489	of	_
58-9	8490-8493	the	_
58-10	8494-8505	participant	_
58-11	8506-8507	’	_
58-12	8508-8509	s	_
58-13	8510-8514	head	_
58-14	8515-8523	relative	_
58-15	8524-8526	to	_
58-16	8527-8530	the	_
58-17	8531-8539	position	_
58-18	8540-8543	and	_
58-19	8544-8555	orientation	_
58-20	8556-8558	of	_
58-21	8559-8562	the	_
58-22	8563-8566	MEG	_
58-23	8567-8574	sensors	_
58-24	8575-8576	.	_

Text=Additional positioning data were collected using a 3D digitizer (Polhemus Fastrak) in order to permit co-localization of MEG activity with the anatomical MRI result for each participant.
59-1	8577-8587	Additional	_
59-2	8588-8599	positioning	_
59-3	8600-8604	data	_
59-4	8605-8609	were	_
59-5	8610-8619	collected	_
59-6	8620-8625	using	_
59-7	8626-8627	a	_
59-8	8628-8630	3D	_
59-9	8631-8640	digitizer	_
59-10	8641-8642	(	_
59-11	8643-8651	Polhemus	_
59-12	8652-8659	Fastrak	_
59-13	8660-8661	)	_
59-14	8662-8664	in	_
59-15	8665-8670	order	_
59-16	8671-8673	to	_
59-17	8674-8680	permit	_
59-18	8681-8696	co-localization	_
59-19	8697-8699	of	_
59-20	8700-8703	MEG	_
59-21	8704-8712	activity	_
59-22	8713-8717	with	_
59-23	8718-8721	the	_
59-24	8722-8732	anatomical	_
59-25	8733-8736	MRI	_
59-26	8737-8743	result	_
59-27	8744-8747	for	_
59-28	8748-8752	each	_
59-29	8753-8764	participant	_
59-30	8765-8766	.	_

Text=Two channels of electro-oculogram (EOG), one vertical and one horizontal, and one channel of electrocardiogram (ECG) were collected simultaneously with MEG.
60-1	8767-8770	Two	_
60-2	8771-8779	channels	_
60-3	8780-8782	of	_
60-4	8783-8800	electro-oculogram	_
60-5	8801-8802	(	_
60-6	8803-8806	EOG	_
60-7	8807-8808	)	_
60-8	8809-8810	,	_
60-9	8811-8814	one	_
60-10	8815-8823	vertical	_
60-11	8824-8827	and	_
60-12	8828-8831	one	_
60-13	8832-8842	horizontal	_
60-14	8843-8844	,	_
60-15	8845-8848	and	_
60-16	8849-8852	one	_
60-17	8853-8860	channel	_
60-18	8861-8863	of	_
60-19	8864-8881	electrocardiogram	_
60-20	8882-8883	(	_
60-21	8884-8887	ECG	_
60-22	8888-8889	)	_
60-23	8890-8894	were	_
60-24	8895-8904	collected	_
60-25	8905-8919	simultaneously	_
60-26	8920-8924	with	_
60-27	8925-8928	MEG	_
60-28	8929-8930	.	_

Text=MEG data were sampled at a rate of 1000 Hz, with a bandpass filter of 0.10 to 330 Hz.
61-1	8931-8934	MEG	_
61-2	8935-8939	data	_
61-3	8940-8944	were	_
61-4	8945-8952	sampled	_
61-5	8953-8955	at	_
61-6	8956-8957	a	_
61-7	8958-8962	rate	_
61-8	8963-8965	of	_
61-9	8966-8970	1000	_
61-10	8971-8973	Hz	_
61-11	8974-8975	,	_
61-12	8976-8980	with	_
61-13	8981-8982	a	_
61-14	8983-8991	bandpass	_
61-15	8992-8998	filter	_
61-16	8999-9001	of	_
61-17	9002-9006	0.10	_
61-18	9007-9009	to	_
61-19	9010-9013	330	_
61-20	9014-9016	Hz	_
61-21	9017-9018	.	_

Text=Head position was monitored continuously throughout the MEG session.
62-1	9019-9023	Head	_
62-2	9024-9032	position	_
62-3	9033-9036	was	_
62-4	9037-9046	monitored	_
62-5	9047-9059	continuously	_
62-6	9060-9070	throughout	_
62-7	9071-9074	the	_
62-8	9075-9078	MEG	_
62-9	9079-9086	session	_
62-10	9087-9088	.	_

Text=Raw data were collected and stored.
63-1	9089-9092	Raw	_
63-2	9093-9097	data	_
63-3	9098-9102	were	_
63-4	9103-9112	collected	_
63-5	9113-9116	and	_
63-6	9117-9123	stored	_
63-7	9124-9125	.	_

Text=Participants were instructed to keep their eyes open and maintain fixation during the 6-minute scan to minimize occipital alpha rhythm.
64-1	9126-9138	Participants	_
64-2	9139-9143	were	_
64-3	9144-9154	instructed	_
64-4	9155-9157	to	_
64-5	9158-9162	keep	_
64-6	9163-9168	their	_
64-7	9169-9173	eyes	_
64-8	9174-9178	open	_
64-9	9179-9182	and	_
64-10	9183-9191	maintain	_
64-11	9192-9200	fixation	_
64-12	9201-9207	during	_
64-13	9208-9211	the	_
64-14	9212-9220	6-minute	_
64-15	9221-9225	scan	_
64-16	9226-9228	to	_
64-17	9229-9237	minimize	_
64-18	9238-9247	occipital	_
64-19	9248-9253	alpha	_
64-20	9254-9260	rhythm	_
64-21	9261-9262	.	_

Text=2.7 MEG data preprocessing Artifact removal, correction for head movement, and downsampling to 250 Hz were conducted offline using Elekta Maxfilter software, with 123 basis vectors, a spatiotemporal buffer of 10 s, and a correlation limit of r=.95.
65-1	9263-9266	2.7	_
65-2	9267-9270	MEG	_
65-3	9271-9275	data	_
65-4	9276-9289	preprocessing	_
65-5	9290-9298	Artifact	_
65-6	9299-9306	removal	_
65-7	9307-9308	,	_
65-8	9309-9319	correction	_
65-9	9320-9323	for	_
65-10	9324-9328	head	_
65-11	9329-9337	movement	_
65-12	9338-9339	,	_
65-13	9340-9343	and	_
65-14	9344-9356	downsampling	_
65-15	9357-9359	to	_
65-16	9360-9363	250	_
65-17	9364-9366	Hz	_
65-18	9367-9371	were	_
65-19	9372-9381	conducted	_
65-20	9382-9389	offline	_
65-21	9390-9395	using	_
65-22	9396-9402	Elekta	_
65-23	9403-9412	Maxfilter	_
65-24	9413-9421	software	_
65-25	9422-9423	,	_
65-26	9424-9428	with	_
65-27	9429-9432	123	_
65-28	9433-9438	basis	_
65-29	9439-9446	vectors	_
65-30	9447-9448	,	_
65-31	9449-9450	a	_
65-32	9451-9465	spatiotemporal	_
65-33	9466-9472	buffer	_
65-34	9473-9475	of	_
65-35	9476-9478	10	_
65-36	9479-9480	s	_
65-37	9481-9482	,	_
65-38	9483-9486	and	_
65-39	9487-9488	a	_
65-40	9489-9500	correlation	_
65-41	9501-9506	limit	_
65-42	9507-9509	of	_
65-43	9510-9515	r=.95	_
65-44	9516-9517	.	_

Text=Cardiac and blink artefacts were removed using a signal-space projection (SSP) approach.
66-1	9518-9525	Cardiac	_
66-2	9526-9529	and	_
66-3	9530-9535	blink	_
66-4	9536-9545	artefacts	_
66-5	9546-9550	were	_
66-6	9551-9558	removed	_
66-7	9559-9564	using	_
66-8	9565-9566	a	_
66-9	9567-9579	signal-space	_
66-10	9580-9590	projection	_
66-11	9591-9592	(	_
66-12	9593-9596	SSP	_
66-13	9597-9598	)	_
66-14	9599-9607	approach	_
66-15	9608-9609	.	_

Text=To facilitate an exploratory comparison with previous research, data were bandpass filtered into four frequency ranges of interest: delta (1–4 Hz), theta (5–9 Hz), alpha (10–15 Hz), and beta (16–29 Hz).
67-1	9610-9612	To	_
67-2	9613-9623	facilitate	_
67-3	9624-9626	an	_
67-4	9627-9638	exploratory	_
67-5	9639-9649	comparison	_
67-6	9650-9654	with	_
67-7	9655-9663	previous	_
67-8	9664-9672	research	_
67-9	9673-9674	,	_
67-10	9675-9679	data	_
67-11	9680-9684	were	_
67-12	9685-9693	bandpass	_
67-13	9694-9702	filtered	_
67-14	9703-9707	into	_
67-15	9708-9712	four	_
67-16	9713-9722	frequency	_
67-17	9723-9729	ranges	_
67-18	9730-9732	of	_
67-19	9733-9741	interest	_
67-20	9742-9743	:	_
67-21	9744-9749	delta	_
67-22	9750-9751	(	_
67-23	9752-9755	1–4	_
67-24	9756-9758	Hz	_
67-25	9759-9760	)	_
67-26	9761-9762	,	_
67-27	9763-9768	theta	_
67-28	9769-9770	(	_
67-29	9771-9774	5–9	_
67-30	9775-9777	Hz	_
67-31	9778-9779	)	_
67-32	9780-9781	,	_
67-33	9782-9787	alpha	_
67-34	9788-9789	(	_
67-35	9790-9795	10–15	_
67-36	9796-9798	Hz	_
67-37	9799-9800	)	_
67-38	9801-9802	,	_
67-39	9803-9806	and	_
67-40	9807-9811	beta	_
67-41	9812-9813	(	_
67-42	9814-9819	16–29	_
67-43	9820-9822	Hz	_
67-44	9823-9824	)	_
67-45	9825-9826	.	_

Text=2.8 MEG beamformer projection Covariance matrices were generated independently for each subject and frequency band, using all recorded data.
68-1	9827-9830	2.8	_
68-2	9831-9834	MEG	_
68-3	9835-9845	beamformer	_
68-4	9846-9856	projection	_
68-5	9857-9867	Covariance	_
68-6	9868-9876	matrices	_
68-7	9877-9881	were	_
68-8	9882-9891	generated	_
68-9	9892-9905	independently	_
68-10	9906-9909	for	_
68-11	9910-9914	each	_
68-12	9915-9922	subject	_
68-13	9923-9926	and	_
68-14	9927-9936	frequency	_
68-15	9937-9941	band	_
68-16	9942-9943	,	_
68-17	9944-9949	using	_
68-18	9950-9953	all	_
68-19	9954-9962	recorded	_
68-20	9963-9967	data	_
68-21	9968-9969	.	_

Text=Covariance matrices were regularized using a value of 4 times the minimum singular value of the unregularized matrix.
69-1	9970-9980	Covariance	_
69-2	9981-9989	matrices	_
69-3	9990-9994	were	_
69-4	9995-10006	regularized	_
69-5	10007-10012	using	_
69-6	10013-10014	a	_
69-7	10015-10020	value	_
69-8	10021-10023	of	_
69-9	10024-10025	4	_
69-10	10026-10031	times	_
69-11	10032-10035	the	_
69-12	10036-10043	minimum	_
69-13	10044-10052	singular	_
69-14	10053-10058	value	_
69-15	10059-10061	of	_
69-16	10062-10065	the	_
69-17	10066-10079	unregularized	_
69-18	10080-10086	matrix	_
69-19	10087-10088	.	_

Text=That is, after estimation of the covariance matrix we regularized the matrix by adding a constant to the diagonal.
70-1	10089-10093	That	_
70-2	10094-10096	is	_
70-3	10097-10098	,	_
70-4	10099-10104	after	_
70-5	10105-10115	estimation	_
70-6	10116-10118	of	_
70-7	10119-10122	the	_
70-8	10123-10133	covariance	_
70-9	10134-10140	matrix	_
70-10	10141-10143	we	_
70-11	10144-10155	regularized	_
70-12	10156-10159	the	_
70-13	10160-10166	matrix	_
70-14	10167-10169	by	_
70-15	10170-10176	adding	_
70-16	10177-10178	a	_
70-17	10179-10187	constant	_
70-18	10188-10190	to	_
70-19	10191-10194	the	_
70-20	10195-10203	diagonal	_
70-21	10204-10205	.	_

Text=The constant added was four times the minimum singular value of the unregularized covariance matrix.
71-1	10206-10209	The	_
71-2	10210-10218	constant	_
71-3	10219-10224	added	_
71-4	10225-10228	was	_
71-5	10229-10233	four	_
71-6	10234-10239	times	_
71-7	10240-10243	the	_
71-8	10244-10251	minimum	_
71-9	10252-10260	singular	_
71-10	10261-10266	value	_
71-11	10267-10269	of	_
71-12	10270-10273	the	_
71-13	10274-10287	unregularized	_
71-14	10288-10298	covariance	_
71-15	10299-10305	matrix	_
71-16	10306-10307	.	_

Text=Voxels were placed on a regular 6-mm3 grid spanning the brain image.
72-1	10308-10314	Voxels	_
72-2	10315-10319	were	_
72-3	10320-10326	placed	_
72-4	10327-10329	on	_
72-5	10330-10331	a	_
72-6	10332-10339	regular	_
72-7	10340-10345	6-mm3	_
72-8	10346-10350	grid	_
72-9	10351-10359	spanning	_
72-10	10360-10363	the	_
72-11	10364-10369	brain	_
72-12	10370-10375	image	_
72-13	10376-10377	.	_

Text=Source orientation at each voxel was based on a nonlinear search for maximum projected signal-to-noise ratio.
73-1	10378-10384	Source	_
73-2	10385-10396	orientation	_
73-3	10397-10399	at	_
73-4	10400-10404	each	_
73-5	10405-10410	voxel	_
73-6	10411-10414	was	_
73-7	10415-10420	based	_
73-8	10421-10423	on	_
73-9	10424-10425	a	_
73-10	10426-10435	nonlinear	_
73-11	10436-10442	search	_
73-12	10443-10446	for	_
73-13	10447-10454	maximum	_
73-14	10455-10464	projected	_
73-15	10465-10480	signal-to-noise	_
73-16	10481-10486	ratio	_
73-17	10487-10488	.	_

Text=The forward solution was based on a dipole model and a single-shell boundary element model.
74-1	10489-10492	The	_
74-2	10493-10500	forward	_
74-3	10501-10509	solution	_
74-4	10510-10513	was	_
74-5	10514-10519	based	_
74-6	10520-10522	on	_
74-7	10523-10524	a	_
74-8	10525-10531	dipole	_
74-9	10532-10537	model	_
74-10	10538-10541	and	_
74-11	10542-10543	a	_
74-12	10544-10556	single-shell	_
74-13	10557-10565	boundary	_
74-14	10566-10573	element	_
74-15	10574-10579	model	_
74-16	10580-10581	.	_

Text=Beamformer projection was performed separately for each subject and frequency range.
75-1	10582-10592	Beamformer	_
75-2	10593-10603	projection	_
75-3	10604-10607	was	_
75-4	10608-10617	performed	_
75-5	10618-10628	separately	_
75-6	10629-10632	for	_
75-7	10633-10637	each	_
75-8	10638-10645	subject	_
75-9	10646-10649	and	_
75-10	10650-10659	frequency	_
75-11	10660-10665	range	_
75-12	10666-10667	.	_

Text=After beamformer projection, source-space signals were normalized by an estimate of projected noise and transformed to standard (MNI) space using FLIRT in FSL.
76-1	10668-10673	After	_
76-2	10674-10684	beamformer	_
76-3	10685-10695	projection	_
76-4	10696-10697	,	_
76-5	10698-10710	source-space	_
76-6	10711-10718	signals	_
76-7	10719-10723	were	_
76-8	10724-10734	normalized	_
76-9	10735-10737	by	_
76-10	10738-10740	an	_
76-11	10741-10749	estimate	_
76-12	10750-10752	of	_
76-13	10753-10762	projected	_
76-14	10763-10768	noise	_
76-15	10769-10772	and	_
76-16	10773-10784	transformed	_
76-17	10785-10787	to	_
76-18	10788-10796	standard	_
76-19	10797-10798	(	_
76-20	10799-10802	MNI	_
76-21	10803-10804	)	_
76-22	10805-10810	space	_
76-23	10811-10816	using	_
76-24	10817-10822	FLIRT	_
76-25	10823-10825	in	_
76-26	10826-10829	FSL	_
76-27	10830-10831	.	_

Text=A Hilbert transform was applied to the time course at each voxel time to derive the analytic signal.
77-1	10832-10833	A	_
77-2	10834-10841	Hilbert	_
77-3	10842-10851	transform	_
77-4	10852-10855	was	_
77-5	10856-10863	applied	_
77-6	10864-10866	to	_
77-7	10867-10870	the	_
77-8	10871-10875	time	_
77-9	10876-10882	course	_
77-10	10883-10885	at	_
77-11	10886-10890	each	_
77-12	10891-10896	voxel	_
77-13	10897-10901	time	_
77-14	10902-10904	to	_
77-15	10905-10911	derive	_
77-16	10912-10915	the	_
77-17	10916-10924	analytic	_
77-18	10925-10931	signal	_
77-19	10932-10933	.	_

Text=The absolute value of this analytic signal was computed to yield the Hilbert envelope, an amplitude envelope of oscillatory power.
78-1	10934-10937	The	_
78-2	10938-10946	absolute	_
78-3	10947-10952	value	_
78-4	10953-10955	of	_
78-5	10956-10960	this	_
78-6	10961-10969	analytic	_
78-7	10970-10976	signal	_
78-8	10977-10980	was	_
78-9	10981-10989	computed	_
78-10	10990-10992	to	_
78-11	10993-10998	yield	_
78-12	10999-11002	the	_
78-13	11003-11010	Hilbert	_
78-14	11011-11019	envelope	_
78-15	11020-11021	,	_
78-16	11022-11024	an	_
78-17	11025-11034	amplitude	_
78-18	11035-11043	envelope	_
78-19	11044-11046	of	_
78-20	11047-11058	oscillatory	_
78-21	11059-11064	power	_
78-22	11065-11066	.	_

Text=The Hilbert envelope at each voxel was downsampled to an effective sampling rate of 1 Hz.
79-1	11067-11070	The	_
79-2	11071-11078	Hilbert	_
79-3	11079-11087	envelope	_
79-4	11088-11090	at	_
79-5	11091-11095	each	_
79-6	11096-11101	voxel	_
79-7	11102-11105	was	_
79-8	11106-11117	downsampled	_
79-9	11118-11120	to	_
79-10	11121-11123	an	_
79-11	11124-11133	effective	_
79-12	11134-11142	sampling	_
79-13	11143-11147	rate	_
79-14	11148-11150	of	_
79-15	11151-11152	1	_
79-16	11153-11155	Hz	_
79-17	11156-11157	.	_

Text=Source space envelope data were smoothed spatially (6 mm3 at full-width half-maximum), and the voxel size was resampled to 3×3×3 mm to facilitate comparison with the fMRI data.
80-1	11158-11164	Source	_
80-2	11165-11170	space	_
80-3	11171-11179	envelope	_
80-4	11180-11184	data	_
80-5	11185-11189	were	_
80-6	11190-11198	smoothed	_
80-7	11199-11208	spatially	_
80-8	11209-11210	(	_
80-9	11211-11212	6	_
80-10	11213-11216	mm3	_
80-11	11217-11219	at	_
80-12	11220-11230	full-width	_
80-13	11231-11243	half-maximum	_
80-14	11244-11245	)	_
80-15	11246-11247	,	_
80-16	11248-11251	and	_
80-17	11252-11255	the	_
80-18	11256-11261	voxel	_
80-19	11262-11266	size	_
80-20	11267-11270	was	_
80-21	11271-11280	resampled	_
80-22	11281-11283	to	_
80-23	11284-11289	3×3×3	_
80-24	11290-11292	mm	_
80-25	11293-11295	to	_
80-26	11296-11306	facilitate	_
80-27	11307-11317	comparison	_
80-28	11318-11322	with	_
80-29	11323-11326	the	_
80-30	11327-11331	fMRI	_
80-31	11332-11336	data	_
80-32	11337-11338	.	_

Text=While strong and sustained correlations between brain regions can lead to beamformer failure, this requires correlations that persist through 30–40% of the period analyzed, unlikely in resting data.
81-1	11339-11344	While	_
81-2	11345-11351	strong	_
81-3	11352-11355	and	_
81-4	11356-11365	sustained	_
81-5	11366-11378	correlations	_
81-6	11379-11386	between	_
81-7	11387-11392	brain	_
81-8	11393-11400	regions	_
81-9	11401-11404	can	_
81-10	11405-11409	lead	_
81-11	11410-11412	to	_
81-12	11413-11423	beamformer	_
81-13	11424-11431	failure	_
81-14	11432-11433	,	_
81-15	11434-11438	this	_
81-16	11439-11447	requires	_
81-17	11448-11460	correlations	_
81-18	11461-11465	that	_
81-19	11466-11473	persist	_
81-20	11474-11481	through	_
81-21	11482-11487	30–40	_
81-22	11488-11489	%	_
81-23	11490-11492	of	_
81-24	11493-11496	the	_
81-25	11497-11503	period	_
81-26	11504-11512	analyzed	_
81-27	11513-11514	,	_
81-28	11515-11523	unlikely	_
81-29	11524-11526	in	_
81-30	11527-11534	resting	_
81-31	11535-11539	data	_
81-32	11540-11541	.	_

Text=2.9 MEG Group Spatial Independent Component Analysis (gsICA) Group spatial ICA was applied to the individual subject data using the GIFT toolbox.
82-1	11542-11545	2.9	_
82-2	11546-11549	MEG	_
82-3	11550-11555	Group	_
82-4	11556-11563	Spatial	_
82-5	11564-11575	Independent	_
82-6	11576-11585	Component	_
82-7	11586-11594	Analysis	_
82-8	11595-11596	(	_
82-9	11597-11602	gsICA	_
82-10	11603-11604	)	_
82-11	11605-11610	Group	_
82-12	11611-11618	spatial	_
82-13	11619-11622	ICA	_
82-14	11623-11626	was	_
82-15	11627-11634	applied	_
82-16	11635-11637	to	_
82-17	11638-11641	the	_
82-18	11642-11652	individual	_
82-19	11653-11660	subject	_
82-20	11661-11665	data	_
82-21	11666-11671	using	_
82-22	11672-11675	the	_
82-23	11676-11680	GIFT	_
82-24	11681-11688	toolbox	_
82-25	11689-11690	.	_

Text=The gsICA approach was selected over group temporal ICA (gtICA) for two reasons: 1) Because components produced by gsICA are not temporally independent, relations among network timecourses can be evaluated; and 2) gtICA of participant timecourses carries the assumption of temporal consistency, limiting its utility in group analysis of resting data.
83-1	11691-11694	The	_
83-2	11695-11700	gsICA	_
83-3	11701-11709	approach	_
83-4	11710-11713	was	_
83-5	11714-11722	selected	_
83-6	11723-11727	over	_
83-7	11728-11733	group	_
83-8	11734-11742	temporal	_
83-9	11743-11746	ICA	_
83-10	11747-11748	(	_
83-11	11749-11754	gtICA	_
83-12	11755-11756	)	_
83-13	11757-11760	for	_
83-14	11761-11764	two	_
83-15	11765-11772	reasons	_
83-16	11773-11774	:	_
83-17	11775-11776	1	_
83-18	11777-11778	)	_
83-19	11779-11786	Because	_
83-20	11787-11797	components	_
83-21	11798-11806	produced	_
83-22	11807-11809	by	_
83-23	11810-11815	gsICA	_
83-24	11816-11819	are	_
83-25	11820-11823	not	_
83-26	11824-11834	temporally	_
83-27	11835-11846	independent	_
83-28	11847-11848	,	_
83-29	11849-11858	relations	_
83-30	11859-11864	among	_
83-31	11865-11872	network	_
83-32	11873-11884	timecourses	_
83-33	11885-11888	can	_
83-34	11889-11891	be	_
83-35	11892-11901	evaluated	_
83-36	11902-11903	;	_
83-37	11904-11907	and	_
83-38	11908-11909	2	_
83-39	11910-11911	)	_
83-40	11912-11917	gtICA	_
83-41	11918-11920	of	_
83-42	11921-11932	participant	_
83-43	11933-11944	timecourses	_
83-44	11945-11952	carries	_
83-45	11953-11956	the	_
83-46	11957-11967	assumption	_
83-47	11968-11970	of	_
83-48	11971-11979	temporal	_
83-49	11980-11991	consistency	_
83-50	11992-11993	,	_
83-51	11994-12002	limiting	_
83-52	12003-12006	its	_
83-53	12007-12014	utility	_
83-54	12015-12017	in	_
83-55	12018-12023	group	_
83-56	12024-12032	analysis	_
83-57	12033-12035	of	_
83-58	12036-12043	resting	_
83-59	12044-12048	data	_
83-60	12049-12050	.	_

Text=Replicating and extending the work of, each frequency range was treated as a session in GIFT to permit exploratory analysis of each band, as well as the mean across bands.
84-1	12051-12062	Replicating	_
84-2	12063-12066	and	_
84-3	12067-12076	extending	_
84-4	12077-12080	the	_
84-5	12081-12085	work	_
84-6	12086-12088	of	_
84-7	12089-12090	,	_
84-8	12091-12095	each	_
84-9	12096-12105	frequency	_
84-10	12106-12111	range	_
84-11	12112-12115	was	_
84-12	12116-12123	treated	_
84-13	12124-12126	as	_
84-14	12127-12128	a	_
84-15	12129-12136	session	_
84-16	12137-12139	in	_
84-17	12140-12144	GIFT	_
84-18	12145-12147	to	_
84-19	12148-12154	permit	_
84-20	12155-12166	exploratory	_
84-21	12167-12175	analysis	_
84-22	12176-12178	of	_
84-23	12179-12183	each	_
84-24	12184-12188	band	_
84-25	12189-12190	,	_
84-26	12191-12193	as	_
84-27	12194-12198	well	_
84-28	12199-12201	as	_
84-29	12202-12205	the	_
84-30	12206-12210	mean	_
84-31	12211-12217	across	_
84-32	12218-12223	bands	_
84-33	12224-12225	.	_

Text=MEG ICA processing generally followed the procedures applied to the fMRI.
85-1	12226-12229	MEG	_
85-2	12230-12233	ICA	_
85-3	12234-12244	processing	_
85-4	12245-12254	generally	_
85-5	12255-12263	followed	_
85-6	12264-12267	the	_
85-7	12268-12278	procedures	_
85-8	12279-12286	applied	_
85-9	12287-12289	to	_
85-10	12290-12293	the	_
85-11	12294-12298	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
85-12	12299-12300	.	_

Text=Reduction steps were applied using principal component analysis.
86-1	12301-12310	Reduction	_
86-2	12311-12316	steps	_
86-3	12317-12321	were	_
86-4	12322-12329	applied	_
86-5	12330-12335	using	_
86-6	12336-12345	principal	_
86-7	12346-12355	component	_
86-8	12356-12364	analysis	_
86-9	12365-12366	.	_

Text=First, subject-specific data reduction was applied, retaining 100 principal components.
87-1	12367-12372	First	_
87-2	12373-12374	,	_
87-3	12375-12391	subject-specific	_
87-4	12392-12396	data	_
87-5	12397-12406	reduction	_
87-6	12407-12410	was	_
87-7	12411-12418	applied	_
87-8	12419-12420	,	_
87-9	12421-12430	retaining	_
87-10	12431-12434	100	_
87-11	12435-12444	principal	_
87-12	12445-12455	components	_
87-13	12456-12457	.	_

Text=Next, group level data reduction was applied to reduce the dataset to 75 principal components.
88-1	12458-12462	Next	_
88-2	12463-12464	,	_
88-3	12465-12470	group	_
88-4	12471-12476	level	_
88-5	12477-12481	data	_
88-6	12482-12491	reduction	_
88-7	12492-12495	was	_
88-8	12496-12503	applied	_
88-9	12504-12506	to	_
88-10	12507-12513	reduce	_
88-11	12514-12517	the	_
88-12	12518-12525	dataset	_
88-13	12526-12528	to	_
88-14	12529-12531	75	_
88-15	12532-12541	principal	_
88-16	12542-12552	components	_
88-17	12553-12554	.	_

Text=Infomax ICA was applied 20 times in ICASSO and the resulting components were clustered.
89-1	12555-12562	Infomax	_
89-2	12563-12566	ICA	_
89-3	12567-12570	was	_
89-4	12571-12578	applied	_
89-5	12579-12581	20	_
89-6	12582-12587	times	_
89-7	12588-12590	in	_
89-8	12591-12597	ICASSO	_
89-9	12598-12601	and	_
89-10	12602-12605	the	_
89-11	12606-12615	resulting	_
89-12	12616-12626	components	_
89-13	12627-12631	were	_
89-14	12632-12641	clustered	_
89-15	12642-12643	.	_

Text=Spatial maps were generated by decomposing the mixed MEG timecourses to yield a set of spatially independent and temporally coherent networks.
90-1	12644-12651	Spatial	_
90-2	12652-12656	maps	_
90-3	12657-12661	were	_
90-4	12662-12671	generated	_
90-5	12672-12674	by	_
90-6	12675-12686	decomposing	_
90-7	12687-12690	the	_
90-8	12691-12696	mixed	_
90-9	12697-12700	MEG	_
90-10	12701-12712	timecourses	_
90-11	12713-12715	to	_
90-12	12716-12721	yield	_
90-13	12722-12723	a	_
90-14	12724-12727	set	_
90-15	12728-12730	of	_
90-16	12731-12740	spatially	_
90-17	12741-12752	independent	_
90-18	12753-12756	and	_
90-19	12757-12767	temporally	_
90-20	12768-12776	coherent	_
90-21	12777-12785	networks	_
90-22	12786-12787	.	_

Text=As with fMRI, subject-specific maps and timecourses were estimated using a back-reconstruction approach based on PCA compression and projection.
91-1	12788-12790	As	_
91-2	12791-12795	with	_
91-3	12796-12800	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
91-4	12801-12802	,	_
91-5	12803-12819	subject-specific	_
91-6	12820-12824	maps	_
91-7	12825-12828	and	_
91-8	12829-12840	timecourses	_
91-9	12841-12845	were	_
91-10	12846-12855	estimated	_
91-11	12856-12861	using	_
91-12	12862-12863	a	_
91-13	12864-12883	back-reconstruction	_
91-14	12884-12892	approach	_
91-15	12893-12898	based	_
91-16	12899-12901	on	_
91-17	12902-12905	PCA	_
91-18	12906-12917	compression	_
91-19	12918-12921	and	_
91-20	12922-12932	projection	_
91-21	12933-12934	.	_

Text=This approach was chosen over alternate reconstruction approaches (e.g., GICA1, GICA2, dual regression) because it provides more accurate estimates for each subject and is more readily interpretable.
92-1	12935-12939	This	_
92-2	12940-12948	approach	_
92-3	12949-12952	was	_
92-4	12953-12959	chosen	_
92-5	12960-12964	over	_
92-6	12965-12974	alternate	_
92-7	12975-12989	reconstruction	_
92-8	12990-13000	approaches	_
92-9	13001-13002	(	_
92-10	13003-13007	e.g.	_
92-11	13008-13009	,	_
92-12	13010-13015	GICA1	_
92-13	13016-13017	,	_
92-14	13018-13023	GICA2	_
92-15	13024-13025	,	_
92-16	13026-13030	dual	_
92-17	13031-13041	regression	_
92-18	13042-13043	)	_
92-19	13044-13051	because	_
92-20	13052-13054	it	_
92-21	13055-13063	provides	_
92-22	13064-13068	more	_
92-23	13069-13077	accurate	_
92-24	13078-13087	estimates	_
92-25	13088-13091	for	_
92-26	13092-13096	each	_
92-27	13097-13104	subject	_
92-28	13105-13108	and	_
92-29	13109-13111	is	_
92-30	13112-13116	more	_
92-31	13117-13124	readily	_
92-32	13125-13138	interpretable	_
92-33	13139-13140	.	_

Text=2.10 MEG feature identification Consistent with standard practice, component quality was assessed both qualitatively, to remove components situated in white matter and ventricles, and quantitatively, using assessments of dynamic range and the ratio of low-frequency to high-frequency power in each component.
93-1	13141-13145	2.10	_
93-2	13146-13149	MEG	_
93-3	13150-13157	feature	_
93-4	13158-13172	identification	_
93-5	13173-13183	Consistent	_
93-6	13184-13188	with	_
93-7	13189-13197	standard	_
93-8	13198-13206	practice	_
93-9	13207-13208	,	_
93-10	13209-13218	component	_
93-11	13219-13226	quality	_
93-12	13227-13230	was	_
93-13	13231-13239	assessed	_
93-14	13240-13244	both	_
93-15	13245-13258	qualitatively	_
93-16	13259-13260	,	_
93-17	13261-13263	to	_
93-18	13264-13270	remove	_
93-19	13271-13281	components	_
93-20	13282-13290	situated	_
93-21	13291-13293	in	_
93-22	13294-13299	white	_
93-23	13300-13306	matter	_
93-24	13307-13310	and	_
93-25	13311-13321	ventricles	_
93-26	13322-13323	,	_
93-27	13324-13327	and	_
93-28	13328-13342	quantitatively	_
93-29	13343-13344	,	_
93-30	13345-13350	using	_
93-31	13351-13362	assessments	_
93-32	13363-13365	of	_
93-33	13366-13373	dynamic	_
93-34	13374-13379	range	_
93-35	13380-13383	and	_
93-36	13384-13387	the	_
93-37	13388-13393	ratio	_
93-38	13394-13396	of	_
93-39	13397-13410	low-frequency	_
93-40	13411-13413	to	_
93-41	13414-13428	high-frequency	_
93-42	13429-13434	power	_
93-43	13435-13437	in	_
93-44	13438-13442	each	_
93-45	13443-13452	component	_
93-46	13453-13454	.	_

Text=Components were separated into artifactual and non-artifactual components.
94-1	13455-13465	Components	_
94-2	13466-13470	were	_
94-3	13471-13480	separated	_
94-4	13481-13485	into	_
94-5	13486-13497	artifactual	_
94-6	13498-13501	and	_
94-7	13502-13517	non-artifactual	_
94-8	13518-13528	components	_
94-9	13529-13530	.	_

Text=Of the 75 components requested from the group ICA, 29 were retained as non-artifactual components; see Fig.
95-1	13531-13533	Of	_
95-2	13534-13537	the	_
95-3	13538-13540	75	_
95-4	13541-13551	components	_
95-5	13552-13561	requested	_
95-6	13562-13566	from	_
95-7	13567-13570	the	_
95-8	13571-13576	group	_
95-9	13577-13580	ICA	_
95-10	13581-13582	,	_
95-11	13583-13585	29	_
95-12	13586-13590	were	_
95-13	13591-13599	retained	_
95-14	13600-13602	as	_
95-15	13603-13618	non-artifactual	_
95-16	13619-13629	components	_
95-17	13630-13631	;	_
95-18	13632-13635	see	_
95-19	13636-13639	Fig	_
95-20	13640-13641	.	_

Text=S2.
96-1	13642-13644	S2	_
96-2	13645-13646	.	_

Text=In the present context these criteria, originally applied previously to fMRI ICA components, also appeared to perform well for MEG.
97-1	13647-13649	In	_
97-2	13650-13653	the	_
97-3	13654-13661	present	_
97-4	13662-13669	context	_
97-5	13670-13675	these	_
97-6	13676-13684	criteria	_
97-7	13685-13686	,	_
97-8	13687-13697	originally	_
97-9	13698-13705	applied	_
97-10	13706-13716	previously	_
97-11	13717-13719	to	_
97-12	13720-13724	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
97-13	13725-13728	ICA	_
97-14	13729-13739	components	_
97-15	13740-13741	,	_
97-16	13742-13746	also	_
97-17	13747-13755	appeared	_
97-18	13756-13758	to	_
97-19	13759-13766	perform	_
97-20	13767-13771	well	_
97-21	13772-13775	for	_
97-22	13776-13779	MEG	_
97-23	13780-13781	.	_

Text=As with fMRI, MEG FNC was defined as the zero-lag cross-correlations among reconstructed timecourses.
98-1	13782-13784	As	_
98-2	13785-13789	with	_
98-3	13790-13794	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
98-4	13795-13796	,	_
98-5	13797-13800	MEG	_
98-6	13801-13804	FNC	_
98-7	13805-13808	was	_
98-8	13809-13816	defined	_
98-9	13817-13819	as	_
98-10	13820-13823	the	_
98-11	13824-13832	zero-lag	_
98-12	13833-13851	cross-correlations	_
98-13	13852-13857	among	_
98-14	13858-13871	reconstructed	_
98-15	13872-13883	timecourses	_
98-16	13884-13885	.	_

